Avelas Biosciences Doses First Patient in Phase 2 Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery
August 3, 2017
News
Avelas Biosciences to Participate in JMP Securities Life Sciences Conference
June 13, 2017
Avelas Biosciences Appoints Steven Chen as Chief Medical Officer
May 4, 2017
Avelas Biosciences to Present at Needham & Company 16th Annual Healthcare Conference
March 29, 2017
Avelas Biosciences Appoints Alexey Vinogradov, Ph.D., to Board of Directors
March 14, 2017
Avelas Biosciences to Present at 29th Annual Roth Conference
March 7, 2017
Avelas Presents Phase 1b Clinical Trial Data for AVB-620 at 2016 San Antonio Breast Cancer Symposium
December 8, 2016
Avelas Announces AVB-620 Presentation at 2016 San Antonio Breast Cancer Symposium
December 1, 2016
Avelas Biosciences Completes Patient Enrollment for AVB-620 Phase 1b Clinical Trial
September 8, 2016
Avelas Biosciences Completes $20 Million Series C Financing
August 17, 2016